Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral semaglutide versus empagliflozin added to metformin in type 2 diabetes
2015-005209-36Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- May 2016
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of semaglutide, empagliflozin and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in glycosylated haemoglobin (HbA1c). Started May 2016; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2015-005209-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005209-36.